Acquisition of shares of Assertio Holdings Inc.
ZYDUSLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Zydus Lifesciences, through its subsidiary Zydus Worldwide DMCC, has signed a definitive agreement to acquire US-based Assertio Holdings Inc. for USD 23.50 per share in an all-cash deal worth approximately USD 166.4 million. Assertio is a Nasdaq-listed pharmaceutical company focused on specialty oncology supportive-care therapies, with key product ROLVEDON® (eflapegrastim-xnst), a USFDA-approved long-acting G-CSF biologic. The transaction is structured as a tender offer followed by a merger, with completion expected in financial year 2026-27. Assertio posted revenues of USD 68.23 million in 2025 and USD 60.09 million in 2024. Post-acquisition, Assertio will be delisted from Nasdaq.
This acquisition gives Zydus an immediate U.S. specialty oncology commercial platform with 170+ community oncology accounts, supporting its strategy to build a differentiated specialty oncology business globally. The deal is positive for Zydus shareholders as it adds an approved drug and established distribution infrastructure in a high-margin segment.